Trial Outcomes & Findings for Effect of CT1812 Treatment on Brain Synaptic Density (NCT NCT03493282)
NCT ID: NCT03493282
Last Updated: 2023-09-07
Results Overview
Number of subjects reported with AEs and the number of AEs reported following administration of the IP summarized by treatment and grouped according to system organ class and preferred term, using descriptive statistics. Summaries of AEs were also presented by severity and by relationship to investigational product. In these summaries, subjects were counted only once per MedDRA term, for the AE of highest severity or least favorable relationship. Summaries were also presented of SAEs and of AEs leading to study withdrawal.
COMPLETED
PHASE1/PHASE2
43 participants
Up to 12 months
2023-09-07
Participant Flow
Location Type: Medical Clinic
Each participant was screened between Day -60 and Day -1 prior to study drug administration. Participants could choose to participate in the optional double-blind extension treatment period of an additional 24 weeks (337 days +/-2).as well as a follow up visit at 2 weeks after the final treatment visit. In the study, 43 patients were enrolled. 23 participants were randomized, and 20 were screen failures.
Participant milestones
| Measure |
300 mg
High Dose CT1812
Active Treatment- CT1812 300 mg: CT1812 Administered as an oral capsule at dose levels of 300 mg
|
100 mg
Low Dose CT1812
Active Treatment -CT1812 100 mg: CT1812 Administered as an oral capsule at dose levels of 100 mg
|
Placebo
Matching Placebo
Placebo: Matching Placebo
|
|---|---|---|---|
|
Primary Double-blind Study (180 Days)
STARTED
|
8
|
8
|
7
|
|
Primary Double-blind Study (180 Days)
COMPLETED
|
5
|
6
|
6
|
|
Primary Double-blind Study (180 Days)
NOT COMPLETED
|
3
|
2
|
1
|
|
Double-blind Extension Study (180 Days)
STARTED
|
3
|
6
|
4
|
|
Double-blind Extension Study (180 Days)
COMPLETED
|
3
|
6
|
4
|
|
Double-blind Extension Study (180 Days)
NOT COMPLETED
|
0
|
0
|
0
|
Reasons for withdrawal
| Measure |
300 mg
High Dose CT1812
Active Treatment- CT1812 300 mg: CT1812 Administered as an oral capsule at dose levels of 300 mg
|
100 mg
Low Dose CT1812
Active Treatment -CT1812 100 mg: CT1812 Administered as an oral capsule at dose levels of 100 mg
|
Placebo
Matching Placebo
Placebo: Matching Placebo
|
|---|---|---|---|
|
Primary Double-blind Study (180 Days)
Adverse Event
|
2
|
2
|
1
|
|
Primary Double-blind Study (180 Days)
Subject Moved
|
1
|
0
|
0
|
Baseline Characteristics
Effect of CT1812 Treatment on Brain Synaptic Density
Baseline characteristics by cohort
| Measure |
300 mg
n=8 Participants
High Dose CT1812
Active Treatment- CT1812 300 mg: CT1812
|
100 mg
n=8 Participants
Low Dose CT1812
Active Treatment- CT1812 100 mg: CT1812
|
Placebo
n=7 Participants
Matching Placebo
Placebo: Matching Placebo
|
Total
n=23 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Continuous
|
69.6 years
STANDARD_DEVIATION 10.9 • n=99 Participants
|
68.0 years
STANDARD_DEVIATION 9.3 • n=107 Participants
|
72.6 years
STANDARD_DEVIATION 5.8 • n=206 Participants
|
70.0 years
STANDARD_DEVIATION 8.8 • n=7 Participants
|
|
Sex: Female, Male
Female
|
4 Participants
n=99 Participants
|
4 Participants
n=107 Participants
|
3 Participants
n=206 Participants
|
11 Participants
n=7 Participants
|
|
Sex: Female, Male
Male
|
4 Participants
n=99 Participants
|
4 Participants
n=107 Participants
|
4 Participants
n=206 Participants
|
12 Participants
n=7 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
8 Participants
n=99 Participants
|
8 Participants
n=107 Participants
|
7 Participants
n=206 Participants
|
23 Participants
n=7 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
1 Participants
n=7 Participants
|
|
Race (NIH/OMB)
White
|
8 Participants
n=99 Participants
|
8 Participants
n=107 Participants
|
6 Participants
n=206 Participants
|
22 Participants
n=7 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Weight
|
76.2 kg
STANDARD_DEVIATION 16.9 • n=99 Participants
|
85.6 kg
STANDARD_DEVIATION 5.0 • n=107 Participants
|
74.8 kg
STANDARD_DEVIATION 9.2 • n=206 Participants
|
79.0 kg
STANDARD_DEVIATION 12.1 • n=7 Participants
|
|
Height
|
170.3 cm
STANDARD_DEVIATION 9.9 • n=99 Participants
|
171.4 cm
STANDARD_DEVIATION 12.5 • n=107 Participants
|
172.1 cm
STANDARD_DEVIATION 12.1 • n=206 Participants
|
171.2 cm
STANDARD_DEVIATION 11.0 • n=7 Participants
|
|
Body Mass Index (BMI)
|
26.3 kg/m^2
STANDARD_DEVIATION 5.7 • n=99 Participants
|
29.5 kg/m^2
STANDARD_DEVIATION 4.1 • n=107 Participants
|
25.2 kg/m^2
STANDARD_DEVIATION 1.8 • n=206 Participants
|
27.1 kg/m^2
STANDARD_DEVIATION 4.5 • n=7 Participants
|
PRIMARY outcome
Timeframe: Up to 12 monthsPopulation: Number of Subjects with Treatment Emergent Adverse Events (TEAE)
Number of subjects reported with AEs and the number of AEs reported following administration of the IP summarized by treatment and grouped according to system organ class and preferred term, using descriptive statistics. Summaries of AEs were also presented by severity and by relationship to investigational product. In these summaries, subjects were counted only once per MedDRA term, for the AE of highest severity or least favorable relationship. Summaries were also presented of SAEs and of AEs leading to study withdrawal.
Outcome measures
| Measure |
300 mg
n=7 Participants
High Dose CT1812
CT1812 300 mg
|
100 mg
n=8 Participants
Low Dose CT1812
CT1812 100 mg
|
Placebo
n=6 Participants
Matching Placebo
|
All Subjects
n=21 Participants
Total
|
|---|---|---|---|---|
|
Number of TEAEs, Related TEAEs, SAEs, and Related SAEs
All TEAEs
|
7 Participants
|
8 Participants
|
6 Participants
|
21 Participants
|
|
Number of TEAEs, Related TEAEs, SAEs, and Related SAEs
Mild TEAEs
|
6 Participants
|
4 Participants
|
4 Participants
|
14 Participants
|
|
Number of TEAEs, Related TEAEs, SAEs, and Related SAEs
Moderate TEAEs
|
1 Participants
|
2 Participants
|
1 Participants
|
4 Participants
|
|
Number of TEAEs, Related TEAEs, SAEs, and Related SAEs
Severe TEAEs
|
0 Participants
|
2 Participants
|
1 Participants
|
3 Participants
|
|
Number of TEAEs, Related TEAEs, SAEs, and Related SAEs
Related TEAEs
|
4 Participants
|
3 Participants
|
4 Participants
|
11 Participants
|
|
Number of TEAEs, Related TEAEs, SAEs, and Related SAEs
TEAEs Leading to Treatment Discontinuation
|
2 Participants
|
2 Participants
|
1 Participants
|
5 Participants
|
|
Number of TEAEs, Related TEAEs, SAEs, and Related SAEs
SAEs
|
0 Participants
|
3 Participants
|
1 Participants
|
4 Participants
|
|
Number of TEAEs, Related TEAEs, SAEs, and Related SAEs
Related SAEs
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: Day 169Population: All patients who received at least one dose of investigational product and had a post-baseline assessment of any of the cognitive and clinical endpoints.
The Distribution Volume Ratio (DVR) was used to determine the correlations with the cognitive and functional endpoints. For 11C UCB J, the imaging outcome measure was DVR as produced by the Simplified Reference Tissue Model (SRTM2) using dynamic scan data from 0 to 60 min and the whole cerebellum as a reference region. Change from baseline is calculated as the observed value minus the baseline value. A negative change from baseline indicates the progression of disease.
Outcome measures
| Measure |
300 mg
n=8 Participants
High Dose CT1812
CT1812 300 mg
|
100 mg
n=8 Participants
Low Dose CT1812
CT1812 100 mg
|
Placebo
n=7 Participants
Matching Placebo
|
All Subjects
Total
|
|---|---|---|---|---|
|
Change From Baseline in the Imaging of [11C] UCB-J PET Distribution Volume Ratio (DVR)
|
-0.043 ratio
Standard Error 0.020
|
-0.019 ratio
Standard Error 0.020
|
0.000 ratio
Standard Error 0.020
|
—
|
SECONDARY outcome
Timeframe: Day 169Population: All patients who received at least one dose of investigational product and had a post-baseline assessment of any of the cognitive and clinical endpoints.
For 18F FDG, the primary imaging outcome measure was the SUVR from 60-90 min post injection using whole cerebellum as a reference region. For SUVR, a composite region was determined, including: prefrontal, lateral temporal, posterior cingulate/precuneus, anterior cingulate, lateral parietal, medial temporal, and lateral occipital regions. Change from baseline is calculated as the observed value minus the baseline value. A negative change from baseline indicates the progression of the disease.
Outcome measures
| Measure |
300 mg
n=8 Participants
High Dose CT1812
CT1812 300 mg
|
100 mg
n=8 Participants
Low Dose CT1812
CT1812 100 mg
|
Placebo
n=7 Participants
Matching Placebo
|
All Subjects
Total
|
|---|---|---|---|---|
|
Change From Baseline in the Imaging of [18F]FDG PET SUV Ratio (SUVR)
|
-0.084 ratio
Standard Error 0.017
|
-0.044 ratio
Standard Error 0.017
|
-0.053 ratio
Standard Error 0.017
|
—
|
SECONDARY outcome
Timeframe: Day 169Population: All patients who received at least one dose of investigational product and had a post-baseline assessment of any of the cognitive and clinical endpoints.
A composite region of AD affected brain regions was determined, including prefrontal, lateral temporal, posterior cingulate/precuneus, anterior cingulate, lateral parietal, medial temporal, and lateral occipital regions. Baseline is defined as the last measurement taken before the first dose of study drug. Change from baseline is calculated as the observed value minus the baseline value. A negative change from baseline indicates the progression of disease.
Outcome measures
| Measure |
300 mg
n=8 Participants
High Dose CT1812
CT1812 300 mg
|
100 mg
n=8 Participants
Low Dose CT1812
CT1812 100 mg
|
Placebo
n=7 Participants
Matching Placebo
|
All Subjects
Total
|
|---|---|---|---|---|
|
Change From Baseline in Volumetric Magnetic Resonance Imaging (MRI)
|
-6.34 cm^3
Standard Error 3.49
|
-5.59 cm^3
Standard Error 3.51
|
-13.85 cm^3
Standard Error 3.39
|
—
|
SECONDARY outcome
Timeframe: Day 169Population: All patients who received at least one dose of investigational product and had a post-baseline assessment of any of the cognitive and clinical endpoints.
For resting state functional MRI, the outcome was ICC. With this approach a map of the total connectivity of each voxel to all other voxels was computed. For ICC, a composite region of AD affected brain regions was determined, including prefrontal, lateral temporal, posterior cingulate/precuneus, anterior cingulate, lateral parietal, medial temporal, and lateral occipital regions. Change from baseline is calculated as the observed value minus the baseline value. A negative change from baseline indicates the progression of disease.
Outcome measures
| Measure |
300 mg
n=8 Participants
High Dose CT1812
CT1812 300 mg
|
100 mg
n=8 Participants
Low Dose CT1812
CT1812 100 mg
|
Placebo
n=7 Participants
Matching Placebo
|
All Subjects
Total
|
|---|---|---|---|---|
|
Change From Baseline in the Imaging of Functional MRI - Intrinsic Connectivity Contrast (ICC)
|
0.005 ratio
Standard Error 0.006
|
-0.008 ratio
Standard Error 0.006
|
-0.006 ratio
Standard Error 0.007
|
—
|
SECONDARY outcome
Timeframe: Day 169Population: The Pharmacodynamic Analysis Set included all subjects who received the investigational product for 6 months and who had both a baseline CSF lumbar puncture and at least one post-dose result for any CSF concentrations.
Change from baseline in CSF Aβ 40, CSF Aβ 42, CSF tau, CSF phospho-tau, CSF neurogranin (NRGN), CSF synaptotagmin, CSF(SNAP25), and CSF neurofilament light (NFL). Change from baseline is calculated as the observed value minus the baseline value.
Outcome measures
| Measure |
300 mg
n=7 Participants
High Dose CT1812
CT1812 300 mg
|
100 mg
n=5 Participants
Low Dose CT1812
CT1812 100 mg
|
Placebo
n=6 Participants
Matching Placebo
|
All Subjects
Total
|
|---|---|---|---|---|
|
Change From Baseline in the Cerebrospinal Fluid (CSF) Biomarkers
SNAP-25 (pg/ml)
|
-3.15 pg/ml
Standard Error 1.54
|
0.74 pg/ml
Standard Error 1.83
|
1.36 pg/ml
Standard Error 1.66
|
—
|
|
Change From Baseline in the Cerebrospinal Fluid (CSF) Biomarkers
Aβ 40 (pg/ml)
|
-594.0 pg/ml
Standard Error 381.57
|
517.70 pg/ml
Standard Error 445.24
|
222.25 pg/ml
Standard Error 397.27
|
—
|
|
Change From Baseline in the Cerebrospinal Fluid (CSF) Biomarkers
Aβ 42 (pg/ml)
|
-32.96 pg/ml
Standard Error 17.55
|
11.62 pg/ml
Standard Error 21.88
|
-13.90 pg/ml
Standard Error 19.66
|
—
|
|
Change From Baseline in the Cerebrospinal Fluid (CSF) Biomarkers
Tau (pg/ml)
|
-84.08 pg/ml
Standard Error 111.96
|
121.22 pg/ml
Standard Error 131.96
|
36.74 pg/ml
Standard Error 120.70
|
—
|
|
Change From Baseline in the Cerebrospinal Fluid (CSF) Biomarkers
Phospho-tau (pg/ml)
|
-7.71 pg/ml
Standard Error 12.60
|
5.80 pg/ml
Standard Error 14.91
|
-4.67 pg/ml
Standard Error 13.59
|
—
|
|
Change From Baseline in the Cerebrospinal Fluid (CSF) Biomarkers
NRGN (pg/ml)
|
-26.79 pg/ml
Standard Error 16.50
|
14.96 pg/ml
Standard Error 19.61
|
-5.54 pg/ml
Standard Error 17.77
|
—
|
|
Change From Baseline in the Cerebrospinal Fluid (CSF) Biomarkers
Synaptotagmin (pg/ml)
|
0.88 pg/ml
Standard Error 2.24
|
6.37 pg/ml
Standard Error 2.64
|
0.68 pg/ml
Standard Error 2.44
|
—
|
|
Change From Baseline in the Cerebrospinal Fluid (CSF) Biomarkers
NFL (pg/ml)
|
210.77 pg/ml
Standard Error 149.24
|
265.74 pg/ml
Standard Error 176.40
|
-24.02 pg/ml
Standard Error 164.56
|
—
|
SECONDARY outcome
Timeframe: Day 169Population: All patients who received at least one dose of investigational product and had a post-baseline assessment of any of the cognitive and clinical endpoints.
The ADAS-Cog11 total score = the sum of all 11 individual items (word recall \[10\]; commands \[5\]; constructional praxis \[5\]; naming objects and fingers \[5\]; ideational praxis \[5\]; orientation \[8\]; word recognition \[12\]; remembering test instructions \[5\]; spoken language \[5\]; word finding \[5\]; and comprehension of spoken language \[5\]). The score range for ADAS-cog 11 is 0-70 where a higher score is worse performance. The ADAS-cog methodology is to sum scores for subscales. The results were calculated using the average change from baseline. Baseline is defined as the last measurement taken before the first dose of study drug is administered. Change is calculated as the observed value minus the baseline value. A negative change from baseline indicates improvement.
Outcome measures
| Measure |
300 mg
n=8 Participants
High Dose CT1812
CT1812 300 mg
|
100 mg
n=8 Participants
Low Dose CT1812
CT1812 100 mg
|
Placebo
n=7 Participants
Matching Placebo
|
All Subjects
Total
|
|---|---|---|---|---|
|
Change From Baseline ADAS-Cog11 (Alzheimer's Disease Assessment Scale - Cognition Subscale)
|
1.78 score on a scale
Standard Error 2.101
|
1.28 score on a scale
Standard Error 2.091
|
1.37 score on a scale
Standard Error 2.144
|
—
|
SECONDARY outcome
Timeframe: Day 169Population: All patients who received at least one dose of investigational product and had a post-baseline assessment of any of the cognitive and clinical endpoints.
The ADAS-Cog13 total score includes all of the items in the ADAS-Cog11 and the delayed word recall and the number cancellation. For the ADAS-cog 13 the range is 0-85 (score range for Delayed Word Recall \[DWR\] score is 0-10 and for Number Cancellation \[NC\] is 0-5, thus the score is ADAS-cog 11\[0-70\] plus the scores for DWR and NC). A higher score indicates worse performance. The ADAS-cog methodology is to sum scores for subscales. The results were calculated using the average change from baseline. Baseline is defined as the last measurement taken before the first dose of study drug. Change is calculated as the observed value minus the baseline value. A negative change from baseline indicates improvement in cognitive function.
Outcome measures
| Measure |
300 mg
n=8 Participants
High Dose CT1812
CT1812 300 mg
|
100 mg
n=8 Participants
Low Dose CT1812
CT1812 100 mg
|
Placebo
n=7 Participants
Matching Placebo
|
All Subjects
Total
|
|---|---|---|---|---|
|
Change From Baseline ADAS-Cog13 (Alzheimer's Disease Assessment Scale - Cognition Subscale)
|
2.62 score on a scale
Standard Error 2.157
|
1.73 score on a scale
Standard Error 2.146
|
1.02 score on a scale
Standard Error 2.178
|
—
|
SECONDARY outcome
Timeframe: Day 169Population: All patients who received at least one dose of investigational product and had a post-baseline assessment of any of the cognitive and clinical endpoints.
The ADAS-Cog14 total score includes all of the items in the ADAS-Cog13 \[0-85\] and the maze item which has a score range of 0-5. Thus, the total score for the ADAS-cog 14 is 0-90 where again a higher score is worst performance. The ADAS-cog methodology is to sum scores for subscales. The results were calculated using the average change from baseline. Baseline is defined as the last measurement taken before the first dose of study drug is administered. Change is calculated as the observed value minus the baseline value. A negative change from baseline indicates improvement in cognitive function.
Outcome measures
| Measure |
300 mg
n=8 Participants
High Dose CT1812
CT1812 300 mg
|
100 mg
n=8 Participants
Low Dose CT1812
CT1812 100 mg
|
Placebo
n=7 Participants
Matching Placebo
|
All Subjects
Total
|
|---|---|---|---|---|
|
Change From Baseline ADAS-Cog14 (Alzheimer's Disease Assessment Scale - Cognition Subscale)
|
1.25 score on a scale
Standard Error 2.544
|
1.42 score on a scale
Standard Error 2.245
|
1.65 score on a scale
Standard Error 2.290
|
—
|
SECONDARY outcome
Timeframe: Day 169Population: All patients who received at least one dose of investigational product and had a post-baseline assessment of any of the cognitive and clinical endpoints.
The ADCS-ADL is a 23-item informant-administered assessment of functional impairment in terms of activities of daily living. Informants respond to 23 questions about the subject's involvement and level of performance across items representing daily living. The questions range from basic to instrumental activities of daily living. Each item is rated from the highest level of independent performance to complete loss. The total score range is from 0-78 with lower scores indicating greater functional impairment. A positive change from baseline indicates improvement in function. The results were calculated using the average change from baseline. Higher scores mean better outcome. Negative mean indicates worsening of function. Positive mean indicates improvement of function.
Outcome measures
| Measure |
300 mg
n=8 Participants
High Dose CT1812
CT1812 300 mg
|
100 mg
n=8 Participants
Low Dose CT1812
CT1812 100 mg
|
Placebo
n=7 Participants
Matching Placebo
|
All Subjects
Total
|
|---|---|---|---|---|
|
Change From Baseline in ADCS-Activities of Daily Living (ADCS-ADL)
|
-3.16 score on a scale
Standard Error 1.646
|
-0.31 score on a scale
Standard Error 1.522
|
2.21 score on a scale
Standard Error 1.641
|
—
|
SECONDARY outcome
Timeframe: Day 169Population: All patients who received at least one dose of investigational product and had a post-baseline assessment of any of the cognitive and clinical endpoints.
The MMSE assesses several aspects of memory and cognitive functioning including orientation, attention, concentration, comprehension, recall, and praxis. The total possible score is 30, with high scores indicating less impairment. Change from baseline is calculated as the observed value minus the baseline value. A positive change from baseline indicates improvement in cognition.
Outcome measures
| Measure |
300 mg
n=8 Participants
High Dose CT1812
CT1812 300 mg
|
100 mg
n=8 Participants
Low Dose CT1812
CT1812 100 mg
|
Placebo
n=7 Participants
Matching Placebo
|
All Subjects
Total
|
|---|---|---|---|---|
|
Change From Baseline in Mini Mental State Exam (MMSE)
|
-2.92 score on a scale
Standard Error 1.540
|
-1.26 score on a scale
Standard Error 1.448
|
-0.74 score on a scale
Standard Error 1.547
|
—
|
SECONDARY outcome
Timeframe: Day 169Population: All patients who received at least one dose of investigational product and had a post-baseline assessment of any of the cognitive and clinical endpoints.
Scores were on a scale of 0 through 3, with 0=no dementia, 0.5=questionable dementia, 1=mild dementia, 2=moderate dementia, and 3=severe dementia. Cognitive and functional abilities that were assessed include Memory; Orientation; Judgment and Problem Solving; Community Affairs; Home and Hobbies; and Personal Care. Memory was considered as the primary driver for scoring and the other categories were secondary. The change from baseline in the CDR-SB total score was analyzed using the mixed model for repeated measures (MMRM). Change from baseline is calculated as the observed value minus the baseline value. Higher scores mean worsening of disease.
Outcome measures
| Measure |
300 mg
n=8 Participants
High Dose CT1812
CT1812 300 mg
|
100 mg
n=8 Participants
Low Dose CT1812
CT1812 100 mg
|
Placebo
n=7 Participants
Matching Placebo
|
All Subjects
Total
|
|---|---|---|---|---|
|
Change From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)
|
0.72 score on a scale
Standard Error 0.421
|
0.39 score on a scale
Standard Error 0.399
|
0.17 score on a scale
Standard Error 0.409
|
—
|
SECONDARY outcome
Timeframe: Day 169Population: All patients who received at least one dose of investigational product and had a post-baseline assessment of any of the cognitive and clinical endpoints.
The scale consists of a format with which a clinician may address clinically relevant overall change, including 15 areas under the domains of cognition, behavior, and social and daily functioning. For ADCS-CGIC, the individual data listing presented the original score on the seven-point scale. In addition, the seven-point score was collapsed to 3 groups, combining scores 1-3 to "Improved", 4 to "No change", and 5-7 to "Worsening". Lower scores indicate improvement.
Outcome measures
| Measure |
300 mg
n=8 Participants
High Dose CT1812
CT1812 300 mg
|
100 mg
n=8 Participants
Low Dose CT1812
CT1812 100 mg
|
Placebo
n=7 Participants
Matching Placebo
|
All Subjects
Total
|
|---|---|---|---|---|
|
Change From Baseline in Alzheimer's Disease Clinical Study - Clinician Global Impression of Change (ADCS-CGIC)
|
4.80 score on a scale
Standard Error 0.279
|
4.50 score on a scale
Standard Error 0.257
|
4.68 score on a scale
Standard Error 0.257
|
—
|
SECONDARY outcome
Timeframe: Day169Population: All patients who received at least one dose of investigational product and had a post-baseline assessment of any of the cognitive and clinical endpoints.
The Cognitive composite included: 1. 6 ADAS-Cog items: word recall, orientation, delayed word recall, word recognition, number cancellation, and maze 2. 4 Neuropsychological Test Battery (NTB) items: Trail Making Test (TMT) A, Trail Making Test (TMT) B, Category Fluency Test (CFT), Digit span. Each individual z-score was calculated by first computing the baseline mean and standard deviation at baseline for all subjects within each individual component. The z-scores were then derived for each subject and timepoint by subtracting the corresponding baseline mean from the observed value and then dividing by the standard deviation at baseline. The sign of the z-score for the following components was reversed when deriving the Composite scores: Word recall, Orientation, Delayed Word Recall, Word Recognition, Maze, TMT A, TMT B. Z-score = 0 represents the population at baseline Positive Z-score = indicates improvement Negative Z-score= indicates worsening
Outcome measures
| Measure |
300 mg
n=8 Participants
High Dose CT1812
CT1812 300 mg
|
100 mg
n=8 Participants
Low Dose CT1812
CT1812 100 mg
|
Placebo
n=7 Participants
Matching Placebo
|
All Subjects
Total
|
|---|---|---|---|---|
|
Change From Baseline in the Cognitive Composite
|
-0.33 Z-Score
Standard Error 0.109
|
-0.11 Z-Score
Standard Error 0.102
|
-0.10 Z-Score
Standard Error 0.109
|
—
|
SECONDARY outcome
Timeframe: Day169Population: All patients who received at least one dose of investigational product and had a post-baseline assessment of any of the cognitive and clinical endpoints.
The memory composite includes 4 ADAS-COG (Alzheimer's Disease Assessment Scale - cognition subscale) items: word recall, orientation, delayed word recall, word recognition. The Memory composite score will be a composite z-score average similar to the Cognitive Composite score but will only be derived using the average of the ADAS-Cog Word Recall, Orientation, Delayed Word Recall, and Word Recognition items. If a subject is missing any of the four items at a timepoint, this composite score will not be derived. The score was calculated using z-scores of the items cited above where: Z-score = 0 represents the population at baseline. Positive Z-score = indicates improvement Negative Z-score= indicates worsening
Outcome measures
| Measure |
300 mg
n=8 Participants
High Dose CT1812
CT1812 300 mg
|
100 mg
n=8 Participants
Low Dose CT1812
CT1812 100 mg
|
Placebo
n=7 Participants
Matching Placebo
|
All Subjects
Total
|
|---|---|---|---|---|
|
Change From Baseline in the Memory Composite
|
-0.49 Z-score
Standard Error 0.201
|
-0.18 Z-score
Standard Error 0.201
|
-0.14 Z-score
Standard Error 0.198
|
—
|
SECONDARY outcome
Timeframe: Day 169Population: All patients who received at least one dose of investigational product and had a post-baseline assessment of any of the cognitive and clinical endpoints.
The Attention composite score included: 1. 1 ADAS-COG (Alzheimer's Disease Assessment Scale -cognition subscale) item: Number Cancellation 2. 1 NTB item: Trail Making Test (TMT) A The Attention composite score will be a composite z-score average derived using the average of the Number Cancellation, Maze item from ADAS-Cog 14, and TMT A items. If a subject missed either of the three items at a timepoint, this composite score was derived. The score was calculated using z-scores of the items cited above where: Z-score = 0 represents the population at baseline. Positive Z-score = indicates improvement Negative Z-score= indicates worsening
Outcome measures
| Measure |
300 mg
n=8 Participants
High Dose CT1812
CT1812 300 mg
|
100 mg
n=8 Participants
Low Dose CT1812
CT1812 100 mg
|
Placebo
n=7 Participants
Matching Placebo
|
All Subjects
Total
|
|---|---|---|---|---|
|
Change From Baseline in Attention Composite
|
-0.01 Z-score
Standard Error 0.158
|
0.15 Z-score
Standard Error 0.132
|
-0.13 Z-score
Standard Error 0.139
|
—
|
SECONDARY outcome
Timeframe: Day 169Population: All patients who received at least one dose of investigational product and had a post-baseline assessment of any of the cognitive and clinical endpoints.
The Executive composite included 1. 0 ADAS-COG (Alzheimer's Disease Assessment Scale - cognition subscale) items 2. 3 NTB (Neuropsychological Test Battery) items: CFT (Category Fluency Test), Digit Span, and Trail Making Test (TMT) B The Executive function composite score will be a composite z-score average derived using the average of the CFT Category Fluency Test), Digit Span, and TMT B items. If a subject is missing any of the three items at a timepoint, this composite score will not be derived. The score was calculated using z-scores of the items cited above where: Z-score = 0 represents the population at baseline. Positive Z-score = indicates improvement Negative Z-score= indicates worsening
Outcome measures
| Measure |
300 mg
n=8 Participants
High Dose CT1812
CT1812 300 mg
|
100 mg
n=8 Participants
Low Dose CT1812
CT1812 100 mg
|
Placebo
n=7 Participants
Matching Placebo
|
All Subjects
Total
|
|---|---|---|---|---|
|
Change From Baseline in the Executive Composite
|
-0.35 Z-score
Standard Error 0.366
|
0.66 Z-score
Standard Error 0.364
|
-0.03 Z-score
Standard Error 0.256
|
—
|
Adverse Events
300 mg
100 mg
Placebo
Serious adverse events
| Measure |
300 mg
n=8 participants at risk
High Dose CT1812
CT1812 300 mg
|
100 mg
n=8 participants at risk
Low Dose CT1812
CT1812 100 mg
|
Placebo
n=7 participants at risk
Matching Placebo
|
|---|---|---|---|
|
Renal and urinary disorders
Ureterolithiasis
|
0.00%
0/8 • Up to 12 months
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Nervous system disorders
Thalamic Infarction
|
0.00%
0/8 • Up to 12 months
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Psychiatric disorders
Psychotic disorder
|
0.00%
0/8 • Up to 12 months
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Nervous system disorders
Seizure
|
0.00%
0/8 • Up to 12 months
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Infections and infestations
Encephalitis
|
0.00%
0/8 • Up to 12 months
|
0.00%
0/8 • Up to 12 months
|
14.3%
1/7 • Number of events 1 • Up to 12 months
|
Other adverse events
| Measure |
300 mg
n=8 participants at risk
High Dose CT1812
CT1812 300 mg
|
100 mg
n=8 participants at risk
Low Dose CT1812
CT1812 100 mg
|
Placebo
n=7 participants at risk
Matching Placebo
|
|---|---|---|---|
|
Infections and infestations
Bronchitis
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/8 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Infections and infestations
Encephalitis
|
0.00%
0/8 • Up to 12 months
|
0.00%
0/8 • Up to 12 months
|
14.3%
1/7 • Number of events 1 • Up to 12 months
|
|
Infections and infestations
Furuncle
|
0.00%
0/8 • Up to 12 months
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Infections and infestations
Upper respiratory tract infection
|
0.00%
0/8 • Up to 12 months
|
25.0%
2/8 • Number of events 4 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/8 • Up to 12 months
|
25.0%
2/8 • Number of events 2 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/8 • Up to 12 months
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Endocrine disorders
Goitre
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/8 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Endocrine disorders
Inappropriate antidiuretic hormone secretion
|
0.00%
0/8 • Up to 12 months
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Metabolism and nutrition disorders
Hyperlipidaemia
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/8 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.00%
0/8 • Up to 12 months
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Psychiatric disorders
Confusional state
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/8 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Psychiatric disorders
Psychotic disorder
|
0.00%
0/8 • Up to 12 months
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Nervous system disorders
Carotid artery stenosis
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/8 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Nervous system disorders
Cerebral ischaemia
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/8 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Nervous system disorders
Cerebral microhaemorrhage
|
0.00%
0/8 • Up to 12 months
|
0.00%
0/8 • Up to 12 months
|
14.3%
1/7 • Number of events 1 • Up to 12 months
|
|
Nervous system disorders
Dizziness
|
12.5%
1/8 • Number of events 3 • Up to 12 months
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Nervous system disorders
Headache
|
37.5%
3/8 • Number of events 3 • Up to 12 months
|
25.0%
2/8 • Number of events 2 • Up to 12 months
|
28.6%
2/7 • Number of events 2 • Up to 12 months
|
|
Nervous system disorders
Seizure
|
0.00%
0/8 • Up to 12 months
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Nervous system disorders
Thalamic infarction
|
0.00%
0/8 • Up to 12 months
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Eye disorders
Eye pain
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/8 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Vascular disorders
Peripheral venous disease
|
0.00%
0/8 • Up to 12 months
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/8 • Up to 12 months
|
12.5%
1/8 • Number of events 2 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/8 • Up to 12 months
|
0.00%
0/8 • Up to 12 months
|
14.3%
1/7 • Number of events 1 • Up to 12 months
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
0.00%
0/8 • Up to 12 months
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/8 • Up to 12 months
|
25.0%
2/8 • Number of events 2 • Up to 12 months
|
14.3%
1/7 • Number of events 1 • Up to 12 months
|
|
Skin and subcutaneous tissue disorders
Swelling face
|
0.00%
0/8 • Up to 12 months
|
0.00%
0/8 • Up to 12 months
|
14.3%
1/7 • Number of events 1 • Up to 12 months
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/8 • Up to 12 months
|
0.00%
0/8 • Up to 12 months
|
14.3%
1/7 • Number of events 1 • Up to 12 months
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/8 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/8 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Renal and urinary disorders
Micturition urgency
|
0.00%
0/8 • Up to 12 months
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Renal and urinary disorders
Pollakiuria
|
0.00%
0/8 • Up to 12 months
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Investigations
Liver function test increased
|
25.0%
2/8 • Number of events 2 • Up to 12 months
|
0.00%
0/8 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Injury, poisoning and procedural complications
Ankle fracture
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/8 • Up to 12 months
|
14.3%
1/7 • Number of events 1 • Up to 12 months
|
|
Injury, poisoning and procedural complications
Tooth fracture
|
0.00%
0/8 • Up to 12 months
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Injury, poisoning and procedural complications
Fall
|
12.5%
1/8 • Number of events 2 • Up to 12 months
|
12.5%
1/8 • Number of events 4 • Up to 12 months
|
14.3%
1/7 • Number of events 1 • Up to 12 months
|
|
Surgical and medical procedures
Carotid endarterectomy
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/8 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Infections and infestations
Cellulitis
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/8 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Infections and infestations
Nasopharyngitis
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/8 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Infections and infestations
Pneumonia
|
0.00%
0/8 • Up to 12 months
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.00%
0/8 • Up to 12 months
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Psychiatric disorders
Anxiety
|
0.00%
0/8 • Up to 12 months
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Nervous system disorders
Cerebral Infarction
|
0.00%
0/8 • Up to 12 months
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
|
0.00%
0/8 • Up to 12 months
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/8 • Up to 12 months
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/8 • Up to 12 months
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Renal and urinary disorders
Hypertonic bladder
|
0.00%
0/8 • Up to 12 months
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Renal and urinary disorders
Ureterolithiasis
|
0.00%
0/8 • Up to 12 months
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Injury, poisoning and procedural complications
Ligament Sprain
|
0.00%
0/8 • Up to 12 months
|
0.00%
0/8 • Up to 12 months
|
14.3%
1/7 • Number of events 1 • Up to 12 months
|
|
Surgical and medical procedures
Cataract Operation
|
0.00%
0/8 • Up to 12 months
|
12.5%
1/8 • Number of events 2 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Surgical and medical procedures
Gingival graft
|
0.00%
0/8 • Up to 12 months
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
|
Surgical and medical procedures
Ureatric Operation
|
0.00%
0/8 • Up to 12 months
|
12.5%
1/8 • Number of events 1 • Up to 12 months
|
0.00%
0/7 • Up to 12 months
|
Additional Information
Chief Medical Officer, Head of R&D
Cogntion Therapeutics Inc
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place